Skip to main content

Table 1 Clinicopathological and molecular characteristics of study patients

From: Small molecule tyrosine kinase inhibitors modulated blood immune cell counts in patients with oncogene-driven NSCLC

Category Group A Group B Group C
No. Patient 34 35 22
Age: median (range) 67.3 (43–85) 69.9 (45–92) 67.1 (55–81)
Gender: female N (%) 22 (64.7%) 17 (48.6%) 10 (45.5%)
Race/ethnicity: N (%)
Non-Hispanic White 16 (47.1%) 32 (91.4%) 17 (77.3%)
Hispanic 1 (2.9%) 1 (2.9%) 4 (18.2%)
Asian 17 (50.0%) 2 (5.7%) 1 (4.5%)
Histology: N (%)
LUAD 33 (97.1%) 25 (74.4%) 14 (63.6%)
LUSC 1 (2.9%) 10 (28.5%) 4 (18.2%)
NSCLC-NOS 0 (0%) 0 (0%) 4 (18.2%)
Driver oncogene mutations: 34 (100%) 0 (0%) 7 (31.8%)
EGFR mutations 24 (70.6%) 0 (0%) 3 (13.6%)
ALK fusions 3 (8.8%) 0 (0%) 2 (9.1%)
HER2 alterations 3 (8.8%) 0 (0%) 1 (4.5%)
MET alterations 3 (8.8%) 0 (0%) 1 (4.5%)
RET fusions 1 (2.9%) 0 (0%) 0 (0%)
  1. Abbreviations: LUAD lung adenocarcinoma, LUSC lung squamous cell carcinoma, NSCLC non-small cell lung cancer, N number, NOS not otherwise specified